CryoPort Inc (NASDAQ:CYRX) had $5.50 million USD in sales for the last 12 months and based on a current price of around $2.00 per share the company yields about 0.00%. The company has generated returns on equity over the last 12 months (-486.50%). It managed to grow its gross profit margin to 30.40% over the past 12 months.
Cryoport, Inc. (CYRX) today declared that it is offering cryogenic logistics solutions that support ProteoGenex, Inc.’s shipping of biological specimens, including PBMCs, BMMCs, frozen tissue, OCT-embedded tissue, blood serum, blood plasma, whole blood, RNA/DNA, and other bio-fluids.
Jerrell Shelton, Chief Executive Officer of Cryoport said “Cryoport is working with ProteoGenex’s biological specimen business to make the transition from cold chain shipping using dry ice to Cryoport’s cryogenic logistics solutions, which practically eliminates the risk of degradation during transport through the use of our dry vapor shippers. As a result, Cryoport is providing ProteoGenex with a more stable, trustworthy and cost-effective approach to frozen transportation for its high-value frozen life sciences materials and products.”
Marina Prilutskaya, Head of Operations of ProteoGenex, Inc., said, “We have chosen to implement Cryoport’s advanced cryogenic logistics solutions because of Cryoport’s longstanding cold chain logistics expertise and proven capability to manage the challenges of transporting precious, temperature-sensitive cryogenically frozen materials. Cryoport’s solutions offer a safer, more valuable and consistent way to transport our biological specimens that will eventually prevent degradation or loss of our product. By utilizing Cryoport’s reusable shippers we will reduce our use of consumable dry ice shipping materials and many of our clients will save more then 50% on shipping and handling costs.”
ProteoGenex is a world leader in the procurement and distribution of biological materials for the biomedical research community, which encompasses biotechnology, pharmaceutical, government, and academic research organizations. ProteoGenex will utilize Cryoport’s cryogenic logistics solutions for the movement of biologic materials internationally from their extensive biorepository to researchers for clinical study and biological research support.
With strategically placed depots in Europe, Asia and North America, Cryoport is able to support cryogenic logistics solutions in more than 90 countries. Cryoport’s cold chain logistics solutions supervise temperatures and record the location of packages throughout the entire logistics shipping. Cryoport is the only cryogenic logistics company in the life sciences industry to provide complete “chain of condition” and “chain of custody” reporting. Cryoport is devoted to quality and, to its knowledge, is the only company that exercises a rigid quality assurance program, which includes data extraction, as well as exacting standards for individual package qualifications and before each shipment. In all areas, Cryoport strives to uphold the highest quality standards when transporting valuable IVF materials, as well as other important life sciences materials.